Zobrazeno 31 - 40
of 107
pro vyhledávání: '"Daniel S Chen"'
Autor:
Suchit Jhunjhunwala, Lawrence Fong, Jiaheng Qiu, Toni K. Choueiri, James A. Reeves, Priti S. Hegde, Christina Schiff, Bernard Escudier, Viktor Gruenwald, Dorothee Nickles, Alpa Thobhani, Richard W. Joseph, Walter M. Stadler, Daniel S. Chen, Elisabeth Piault-Louis, Alain Ravaud, Riccardo Danielli, Thomas E. Hutson, John D. Hainsworth, Martin Gore, W. Kimryn Rathmell, Sergio Bracarda, Michael B. Atkins, Sumanta K. Pal, Mahrukh Huseni, Robert J. Motzer, Gregg Fine, Thomas Powles, Brian I. Rini, David F. McDermott, Mario Sznol, Cristina Suarez
Publikováno v:
Nature medicine. 24(6)
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma. Co-primary endpoints w
Autor:
Leisha A Emens, Fadi S Braiteh, Philippe Cassier, Jean-Pierre DeLord, Joseph Paul Eder, Xiaodong Shen, Yuanyuan Xiao, Yan Wang, Priti S Hegde, Daniel S Chen, Ian Krop
Publikováno v:
Cancer Research. 75:PD1-6
Background: Metastatic triple-negative breast cancer (TNBC) is associated with a poor prognosis and has no targeted therapy options. Programmed death-ligand 1 (PD-L1) expression is more prevalent in TNBC than in other breast cancer subtypes. PD-L1 ma
Autor:
Scott N. Gettinger, Ahmad Mokatrin, Daniel S. Chen, Priti S. Hegde, David F. McDermott, Yuanyuan Xiao, Donald P. Lawrence, Leora Horn, F. Stephen Hodi, John D. Powderly, J. A. Sosman, Omid Hamid, Ira Mellman, Jean-Charles Soria, Michael S. Gordon, Marcin Kowanetz, Hartmut Koeppen, Maya Leabman, Roy S. Herbst, Gregg Fine, Sandra Rost, Holbrook E Kohrt
Publikováno v:
Nature. 515:563-567
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing t
Autor:
Thomas Davis, Patrick Soon-Shiong, Edward Cha, Prasad S. Adusumilli, Jane L. Grogan, Charles G. Drake, Adi Diab, Rom Leidner, Adrian Bot, Gordon J. Freeman, Bryan Irving, Salil Patel, Ramy Ibrahim, Daniel S. Chen, David Tuck, Elizabeth E. Evans, Shane A. Olwill, Mark Cornfeld, Thomas W. Dubensky, Frédéric Triebel, Roger D. Dansey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
This report is a summary of ‘New Cancer Immunotherapy Agents in Development’ program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland
Autor:
Mark Stroh, Maria Anderson, Jacek Jassem, Ira Gore, Eric Van Cutsem, Daniel S. Chen, Ilsung Chang, Herbert Hurwitz, Guillem Argiles, Roel Funke, Bruce McCall, Fernando Rivera, Priti S. Hegde, Zev A. Wainberg, Rocio Garcia-Carbonero, Niall C. Tebbutt, Eric Wakshull, Ina Rhee, Fadi Braiteh, Weilan Ye
Publikováno v:
The oncologist, vol 22, iss 4
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The Oncologist
Lessons LearnedThese negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::323fa8b11ccf3c71f7ea9646d90b1e21
https://escholarship.org/uc/item/6597s3st
https://escholarship.org/uc/item/6597s3st
Autor:
Sumanta K. Pal, Thomas Powles, Alpa Thobhani, Brian I. Rini, Jiaheng Qiu, Lawrence Fong, James A. Reeves, Christina Schiff, W. Kimryn Rathmell, Bernard Escudier, Priti S. Hegde, Elisabeth Piault-Louis, David F. McDermott, Sergio Bracarda, Michael B. Atkins, Toni K. Choueiri, Thomas E. Hutson, Mahrukh Huseni, Gregg Fine, Alain Ravaud, Riccardo Danielli, Martin Gore, Viktor Gruenwald, Daniel S. Chen, Robert J. Motzer, John D. Hainsworth, Richard W. Joseph, Dorothee Nickles, Walter M. Stadler, Suchit Jhunjhunwala, Mario Sznol, Cristina Suarez
Publikováno v:
Nature Medicine. 24:1941-1941
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun. It should have been Atezo + bev vs atezo. The error has been corrected in the HTML and PDF
Autor:
Kai H. Barck, Rafael Molina, Olivia Hwang, Ann De Mazière, David Kan, Adrian M. Jubb, Maike Schmidt, Louie Naumovski, Judith Klumperman, Tanya Smyczek, Mallika Singh, Daniel S. Chen, Ian Kasman, Priti S. Hegde, Qinghua Song, Rupal Desai, Jason H. Cheng, Mahrukh Huseni, Weilan Ye, Yin Zhang, Stacey Yeung, Anthony Lima, William F. Forrest, Richard A.D. Carano, Jeffrey Eastham-Anderson, Leisa Johnson, Michelle Nannini, Mark S. Dennis
Publikováno v:
Journal of Clinical Investigation. 123:3997-4009
Many oncology drugs are administered at their maximally tolerated dose without the knowledge of their optimal efficacious dose range. In this study, we describe a multifaceted approach that integrated preclinical and clinical data to identify the opt
Autor:
Heidi S. Phillips, Stefanie S. Jurinka, Hartmut Koeppen, Stefan Scherer, Ru Fang Yeh, Xiumin Wu, Anne C Clermont, C. David James, Ganesh Kolumam, Mallika Singh, Tomoko Ozawa, Alicia S. Chung, Carlos Bais, Daniel S. Chen, Jean Philippe Stephan, Matthew J. Brauer, Peng Yue, Rachel Tam, Maike Schmidt, Napoleone Ferrara, Priti S. Hegde, Guanglei Zhuang, Jenny Yao, Joshua S. Kaminker, Sandra M. Swain, Adrian M. Jubb, Benjamin Haley, Sherry X. Yang, Zora Modrusan, Jason H. Cheng
Publikováno v:
Clinical Cancer Research. 19:3681-3692
Purpose: The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in patients. Experimental Design: Surrogate
Autor:
Daniel S. Chen, Rebecca Elliott, Dafeng Chen, Priti S. Hegde, Stefan Scherer, Coen Bernaards, Adrian M. Jubb, Nicole F. Li, Y. Gloria Meng
Publikováno v:
Clinical Cancer Research. 19:929-937
Purpose: We evaluated the prognostic and predictive use of circulating VEGF-A levels in phase III trials of bevacizumab in colorectal cancer, lung cancer, and renal cell carcinoma. Methods: Baseline plasma samples from 1,816 patients were analyzed fo
Autor:
Daniel S. Chen, Hsuan Lin, Chao-Chin Chang, Yu-Hsin Chen, Yuan-Man Hsu, Chiu-Ying Tang, Yu-Lin Chen, Yu-Heng Su, Jiunn-Horng Lin
Publikováno v:
Comparative Immunology, Microbiology and Infectious Diseases. 36:9-16
A total of 499 Salmonella isolates including 9 serovars from humans and various animal hosts were collected to compare prevalence of integron and antimicrobial resistance. The integron and gene cassette were detected by PCR, and then the gene cassett